Tag: anti-obesity drugs

Market News

Eli Lilly Stock Slides on Bearish GLP-1 Outlook: Our Take

Eli Lilly's stock just took a 6% hit after analysts warned the GLP-1 obesity market might be overhyped—with smaller size...

19/03/2026

3 views

Read More

Altcoins

Top Stock Movers Midday: MOS, TME, DAL, UBER, LLY Surge or Slide

On March 17, 2026, stocks swung wildly midday—Mosaic and Delta soared while Tencent Music crashed over 20%. Geopolitical chaos in...

19/03/2026

3 views

Read More

Market News

Eli Lilly Downgrade: Is Obesity Drug Hype Overblown?

HSBC just slammed Eli Lilly with a rare downgrade, claiming the obesity drug boom is overhyped and the market won't...

19/03/2026

2 views

Read More

Altcoins

Novo Nordisk Downgrade: Semaglutide Patent Risks in 2026

TD Cowen just downgraded Novo Nordisk to Hold, slashing the price target as semaglutide patent losses loom in key markets....

10/03/2026

4 views

Read More

Global Companies

Eli Lilly Boosts Employer Coverage for Obesity Drugs

Eli Lilly just rolled out a program that could finally make powerful obesity medications affordable through your job's benefits. What...

05/03/2026

3 views

Read More

Altcoins

Novo Nordisk Ireland Expansion Challenges Eli Lilly

Novo Nordisk just poured over $500 million into an Irish facility to ramp up production of their game-changing Wegovy pill....

02/03/2026

3 views

Read More

Market News

Novo Nordisk CagriSema: Next Steps After Trial Setback

Novo Nordisk's CagriSema showed 23% weight loss but fell short of Zepbound's results in a head-to-head trial, sending shares tumbling....

26/02/2026

2 views

Read More

Market News

Novo Nordisk Stock Tumbles After CagriSema Trial Setback

Novo Nordisk's next big obesity hope, CagriSema, just fell short in a crucial head-to-head trial against a rival powerhouse—triggering a...

26/02/2026

2 views

Read More

Altcoins

Novo Nordisk Plunges: CagriSema Trial Falls Short

When Novo Nordisk's next-generation obesity shot CagriSema posted weaker weight loss numbers than expected against a key rival, shares cratered...

26/02/2026

3 views

Read More

Market News

Eli Lilly Widens Lead in Obesity Drug Race Over Novo Nordisk

Eli Lilly just landed another major blow to Novo Nordisk in the high-stakes obesity drug battle. With Zepbound showing superior...

24/02/2026

2 views

Read More